Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
 
Online Report Subscribers, Click Here
Pricing and Ordering Information
ClearState

China’s Anti-Cancer Drug Market Report 2008
Report #DHP9000 - December 2008

According to the Chinese Ministry of Health (MOH), there are 2.127 million Chinese patients with newly diagnosed tumors (both benign and malignant) each year; among which 1.06 million were newly diagnosed cancer patients. Cancer has become the leading cause for mortality in both urban and rural China. The cancer mortality rate of urban Chinese residents was 140.47/100,000 (21.82% of all urban deaths); the cancer mortality rate of rural Chinese residents was 111.57/100,000 (16.50% of all rural deaths), according to the national statistics data.

In the Chinese hospital drug market, sales of anti-cancer drugs have rose steadily in recent years. During 2003-2005, the annual compound growth rate of anti-cancer drug sales was approximately 24.53%. In 2006, due to the national campaign on anti-commercial bribery as well as other related government policies, the market growth of anti-cancer drugs slowed down to 11.10%. However, the growth of the anti-cancer drug market regained its momentum and reached a 22.24% annual growth rate in 2007. 2007’s total market size for anti-cancer drugs was RMB 25.45 billion RMB (USD 3.63 billion at a 7:1 USD:RMB exchange rate).

This report systemically analyzes the Chinese anti-cancer drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration SFDA). Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions.

This China Anti-cancer Drug Market Report is a must-have for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies.

 

Ordering Information

Title

 Report# Publication
Date		 List Price

China’s Anti-Cancer Drug Market Report 2008

DHP9000

 December 2008

$8,000
Order Online:
Single User only (Please call for corporate subscription pricing)		   Print + PDF PDF Only

Save $100 off the regular print only price when you order online.

Methodology

Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.

 

TABLE OF CONTENTS

METHODOLOGY FOR THE CHINA DRUG MARKET REPORTS 2008

THE CHINA ANTI-CANCER DRUG MARKET REPORT 2008

PROLOGUE

Section 1:  Basic Concepts of Tumor

Section 2:  Basic Classifications of Tumor

Section 2:  Basic Types of Tumor

Section 4:  Summary of Treatment Options for Common Cancers in China

Section 5:  Summary of Cancer Incidences

Cancer Incidence in the World

Cancer Incidence and Mortality in China

 

CHAPTER I: SUMMARY OF ANTI-CANCER DRUGS IN CHINA

Section 1:  Classifications of Anti-cancer Drugs

Alkaloid and other natural products

Cytotoxic antibiotics and related products

Anti-metabolites

Alkylating agents

Other types

Section 2:  History of Anti-cancer Drug Development in China

Generics vs. Innovative Anti-cancer Drugs in China

Anti-cancer Drug Production Capacity (1996-2006)

 

CHAPTER II: SUMMARY OF GLOBAL MARKETS OF ANTI-CANCER DRUGS

Section 1:  New Anti-cancer Drugs Approved in 2007

New Molecular Entity (NME)

New Biologics

Section 2:  Summary of Global Anti-cancer Drug Market in 2007

The Top 10 Best Selling Therapeutic Categories

Anti-cancer Drugs Among the Top 50 Best Selling Drugs

 

CHAPTER III: MARKET ANALYSIS OF CHINA’S ANTI-CANCER DRUGS

Section 1:  Hospital Market Sizes of Anti-cancer Drugs in China (2003-2007)

Section 2: Analysis of Chinese Hospital Market Shares of Anti-cancer Drugs by Categories (2004-2007)

Section 3:  Hospital Market Shares of the Top 20 Anti-cancer Drugs in China (2006-2007)

Section 4:  Hospital Market Shares of Major Anti-cancer Drug Manufacturers (2006-2007)

Section 5:  Market Share Analysis of Key Anti-cancer Drugs by Categories in 2007

Immune-stimulants

Manufacturers, Market Sizes and Shares for Recombinant G-CSF

Manufacturers, Market Sizes and Shares for Lentinan

Manufacturers, Market Sizes and Shares for Human Interleukin-2

Natural Products

Manufacturers, Market Sizes and Shares for Paclitaxel

Manufacturers, Market Sizes and Shares for Docetaxel

Manufacturers, Market Sizes and Shares for Vinorebine

Anti-metabolites

Manufacturers, Market Sizes and Shares for Capecitabine

Manufacturers, Market Sizes and Shares for Gemcitabine

Manufacturers, Market Sizes and Shares for Pemetrexed

Cytotoxic antibiotics and Related drugs

Manufacturers, Market Sizes and Shares for Epirubicin

Manufacturers, Market Sizes and Shares for Pirarubicin

Aromatase Inhibitors (AI) and Related Products

Manufacturers, Market Sizes and Shares for Letrozol

Manufacturers, Market Sizes and Shares for Anastrozole

Manufacturers, Market Sizes and Shares for Flutamide

Hormone and Related Products

Manufacturers, Market Sizes and Shares for Triptorelin

Manufacturers, Market Sizes and Shares for Goserelin

Manufacturers, Market Sizes and Shares for Leuprorelin

Alkylating Agents

Manufacturers, Market Sizes and Shares for Isophosphamide

Manufacturers, Market Sizes and Shares for Busulfan

All Other Anti-cancer Drugs

Manufacturers, Market Sizes and Shares for Oxaliplatin

Manufacturers, Market Sizes and Shares for Rituximab

Manufacturers, Market Sizes and Shares for Gefitinib

CHAPTER IV: LIST OF BRAND NAMES, GENERIC NAMES OF ANTI-CANCER DRUGS AND THEIR CORRESPONDING MANUFACTURERS IN CHINA

 

CHAPTER V: PACKAGE AND PRICES OF ANTI-CANCER IN CHINA AND ANTI-CANCER DRUGS ON THE NATIONAL HEALTHCARE INSURANCE COVORAGE LIST

Section 1:  Package, Unit, Quality Certification (GMP generics or Patent-protected), Retail Price of Anti-cancer Drugs and Their Manufacturers

Section 2:  Anti-cancer Drugs On the National Healthcare Insurance and Work-related Insurance Lists

Types of Insurance, Formula and Reimbursement Restriction

 

CHAPTER VI: REGULATORY AND GOVERNMENT POLICIES FOR ANTI-CANCER DRUGS IN CHINA

CHAPTER VII: CURRENT ANTI-CANCER DRUG DEVELOPMENT IN CHINA

Section 1:  Pipeline Assessment of Western Anti-cancer Drugs Under Clinical Studies

Section 2:  Pipeline Assessment of Chinese Natural Anti-cancer Products under Clinical Studies

 

EXHIBITS

TABLES

Table A:     Hospital Coverage for Drug Prescription and Purchasing Data Monitor and Tracking in China

Table 1:     Comparison of Benign Tumors with Malignant Tumors

Table 2:     Cancer Disease Rates in China in Recent Years

Table 3:     The Bi-weekly Tumor Disease Morbidity Rates for Different Age Group

Table 4:     Tumor Mortalities in China (MOH)

Table 5:     Newly Approved Anti-cancer NMEs Worldwide in 2007

Table 6:     Newly Approved Anti-cancer Biologics Worldwide in 2007

Table 7:     Top 10 Best Selling Therapeutic Categories in 2007

Table 8:     Anti-cancer Drugs Among the Top 50 Best Selling Drugs in 2006

Table 9:     Chinese Hospital Market Shares of Cancer Drug Categories (2004 - 2007)

Table 9-1:  Chinese Hospital Sales of Cancer Drug Categories (2004 - 2007)

Table 10:   Chinese Hospital Market Shares of the Top 20 Cancer Drugs (2006 -2007)

Table 11:   Chinese Hospital Shares of the Top Pharmaceutical Companies in the Chinese Anti-cancer Drug Market (2006- 2007)

Table 12:   Ranking of Top 5 Anti-cancer Drugs in Each Category by Hospital Utilization (Revenue) 2007

Table 13:   Manufacturers, Market Sizes and Shares for Recombinant G-CSF 2007

Table 14:   Manufacturers, Market Sizes and Shares for Lentinan 2007

Table 15:   Manufacturers, Market Sizes and Shares for rh-Interleukin-2 2007

Table 16:   Manufacturers, Market Sizes and Shares for Paclitaxel 2007

Table 17:   Manufacturers, Market Sizes and Shares for Docetaxel 2007

Table 18:   Manufacturers, Market Sizes and Shares for Vinorebine 2007

Table 19:   Manufacturers, Market Sizes and Shares for Gemcitabine 2007

Table 20:   Manufacturers, Market Sizes and Shares for Pemetrexed 2007

Table 21:   Manufacturers, Market Sizes and Shares for Epirubicin 2007

Table 22:   Manufacturers, Market Sizes and Shares for Pirarubicin 2007

Table 23:   Manufacturers, Market Sizes and Shares for Letrozol 2007

Table 24:   Manufacturers, Market Sizes and Shares for Anastrozole 2007

Table 25:   Manufacturers, Market Sizes and Shares for Flutamide 2007

Table 26:   Manufacturers, Market Sizes and Shares for Triptorelin 2007

Table 27:   Manufacturers, Market Sizes and Shares for Ifosfamide 2007

Table 28:   Manufacturers, Market Sizes and Shares for Busulfan 2007

Table 29:   Manufacturers, Market Sizes and Shares for Oxaliplatin 2007

Table 30:   Brand and Generic Names of Anti-cancer Drugs and Manufacturers in China

Table 31:   Packages and Retail Prices of Anti-cancer Drugs in China

Table 32:   Anti-cancer Drugs Listed on the National Healthcare Insurance Coverage List and on the Worker’s Injury Insurance List

 

FIGURES

Figure 1:    Age Distribution of Sampled Chinese Population

Figure 2:    Annual Production of Anti-cancer Drugs in China (1993-2007)

Figure 3:    Total Sales and Annual Growth Rates of Anti-cancer Drug Market in China (2003-2007)

 

THE TOP 20 PHARMACEUTICAL COMPANIES (WITH AT LEAST >1.3% OF THE CHINA ANTI-CANCER DRUG MARKET) IN 2007

Jiangsu Hansen Pharmaceutical Co., Ltd.(Hansen Pharma)

Jiangsu Hengrui Medicine Co., Ltd

Novartis

Pfizer

Roche

sanofi-aventis

Sichuan Diao Jiuhong Group Pharmaceutical Co

AstraZeneca

Bristol-Myers Squibb

Eli Lilly & Co

Guizhou Baiqiang Pharmaceutical Co., Ltd

Hainan Zhonghe Pharmaceutical Co., Ltd

Jinling Pharmaceutical Co. Ltd

Livzon Pharmaceutical Group Inc.

Nanjing Kanghai Pharmaceutical Co., Ltd

Nanjing Sike Pharmaceutical Co., Ltd

Qilu Pharmaceutical Co., Ltd

SciClone Pharmaceuticals Italy S.R.L.

Shenzhen Wanle Pharmaceutical Co,.Ltd

Zhejiang Hisun Pharmaceutical Co,.Ltd

 

 

Draco Healthcare Consulting is the leader in the China-focused healthcare consulting business. They serve leading pharmaceutical and biotech companies both inside and outside of China to make better medicines for China. www.dracohealthcare.com

*The print version of this report costs an additional $500 when purchased in addition to the PDF.

To order reports or obtain information about special pre-publication offers from within the U.S., contact sales@medtechinsight.com. From outside the U.S., contact internationalsales@medtechinsight.com. You can also call 1.949.453.0071 (or toll-free within the U.S. at 1.888.290.2225) or fax 1.949.453.0072.

 

The Newsletter | The Principals | Reports | Conferences | Physician Surveys | Consulting | Contact Us | Home